Pharmaceutical Forum Concluded Successfully

ECThe final report of the Pharmaceutical Forum has been presented in Brussels setting out principles and recommendations on three key challenges in the pharmaceutical landscape. Firstly, how to improve information on diseases and treatments, secondly, how to compare medicines and identify the most effective ones and thirdly how to balance access and reward for innovation within limited healthcare budgets. The Pharmaceutical Forum was co-chaired by Günter Verheugen, Vice-President of the European Commission, and Commissioner Androulla Vassiliou. This meeting marks the end of a 3-year mandate. The Forum brought together Member States and stakeholders, including patient organisations, health professionals, industry and insurers. The final report comprises a set of principles and recommendations to increase cooperation in three key areas.

Vice President Verheugen, responsible for enterprise and industry policy said: "The Forum's recommendations can lead to important savings and permit a better reward for pharmaceutical innovation. I call upon industry and national authorities to help implementing these recommendations to the benefit of the patients and health care budget."

Commissioner Vassiliou, responsible for health policy, said: "Patients deserve prompt and equal access to the best medicinal products available, and EU cooperation on the relative effectiveness of drugs will help achieve that goal. I also welcome the concrete recommendations on information to patients on diseases and treatments as a major contribution to EU public health promotion policy."

Information to patients on diseases and treatments

The Forum has adopted recommendations to enhance access to and quality of information, such as:

  • Enhance quality of information: Core quality principles for the development of information to patients will enhance the quality of information by providing a clear and defined framework and also identify poor quality information. The Forum invites all health actors to refer to the agreed principles. The ban on advertising of prescription medicines should continue.
  • Increase accessibility: More information to citizens in effective communication formats should be provided (electronic and non-electronic means), taking account of local traditions, healthcare systems and languages.
  • Generation of information by making the best use of all actors: The Forum recommends Member States, the Commission and health actors to consider new collaborations in the field of information to patients. Such collaborations should respect the minimum ethical requirements: transparency, disclosure of financial and other support as well as definition of responsibilities.

Relative effectiveness

Member States, payers and patients face the common challenge of containing health care budgets, including pharmaceutical costs, while promoting and sustaining innovation properly. They therefore need to recognize the value of identifying the most effective medicines. The group reached agreement on:

  • Working definitions and good practice principles for Relative Effectiveness Assessment. These could serve as a basis for voluntary collaboration at EU level. A checklist to use these principles could provide a basis for self assessment at national level.
  • A stocktaking exercise on the existing methods.
  • A common analysis of existing technical and legal barriers to the development of relevant data.

Pricing and reimbursement

Final pricing and reimbursement decisions are usually required before patients can access new health solutions and innovative companies can obtain reward for their research. Although pricing and reimbursement decisions are made by individual Member States, they share the concern on balancing access and reward with limited resources. Concrete recommendations promote:

  • Optimal use of resources: A toolbox of knowledge should help to use limited resources optimally. The Group also discussed specific mechanisms like risk-sharing/conditional pricing and tendering and adopted Guiding Principles to help national authorities finding a balance between expenditure, access and innovation.
  • Access to medicines: The work focused on specific access problems related to small markets and to orphan medicines.
  • Reward of innovation: The expected value of innovation and potential reward mechanisms for innovative medicines have been analyzed in order to better match public health needs and long-term investments in R&D.

Follow up

Member States and stakeholders are invited to implement the recommendations of the Forum. The Commission will provide support to the strengthening of the cooperation tools. All background documents related to the work of the Pharmaceutical Forum are available at: http://ec.europa.eu/pharmaforum

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...